FOR IMMEDIATE RELEASE AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020 San Jose, CA, April 16, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused […]
AnPac Bio Developed and Completed Evaluations of New Generation Cancer Detection Sensor with Improved Performance San Jose, CA, March 9, 2021 – AnPac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that […]
AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement San Jose, CA, March 5, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that on March 4, 2021, the Company […]
China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility) San Jose, CA, February 8, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening […]
FOR IMMEDIATE RELEASE AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection | Continues to Innovate and Build Strong IP Portfolio San Jose, CA, February 1, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the […]
AnPac Bio Makes Significant Progress in Detecting Pre-cancer Diseases andRecorded Over 20 Types of Pre-cancer Diseases San Jose, CA, December 14, 2020 – AnPac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today […]
Anpac Bio Announces Change of Auditor San Jose, CA, December 4, 2020 – Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the resignation of Ernst & Young Hua Ming LLP (“EY”), […]
FOR IMMEDIATE RELEASE AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020 San Jose, CA, November 25, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening […]
Anpac Bio Announces Appointment of New Independent Director San Jose, CA, November 16, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that Professor Jianhua Shao has been appointed as an independent director and a member […]
FOR IMMEDIATE RELEASE AnPac Bio US Completes COVID-19 Antibody Test Verification and Approved to Begin Commercial Testing San Jose, CA, November 10, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the Company has completed […]